DE60213386D1 - Geldanamycinderivate zur krebsbehandlung - Google Patents

Geldanamycinderivate zur krebsbehandlung

Info

Publication number
DE60213386D1
DE60213386D1 DE60213386T DE60213386T DE60213386D1 DE 60213386 D1 DE60213386 D1 DE 60213386D1 DE 60213386 T DE60213386 T DE 60213386T DE 60213386 T DE60213386 T DE 60213386T DE 60213386 D1 DE60213386 D1 DE 60213386D1
Authority
DE
Germany
Prior art keywords
geldanamycine
derivatives
cancer treatment
host
vivo activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213386T
Other languages
English (en)
Other versions
DE60213386T2 (de
Inventor
M Snader
Rao Vishnuvajjala
G Hollingshead
A Sausville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE60213386D1 publication Critical patent/DE60213386D1/de
Application granted granted Critical
Publication of DE60213386T2 publication Critical patent/DE60213386T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60213386T 2001-03-30 2002-03-28 Geldanamycinderivate zur krebsbehandlung Expired - Lifetime DE60213386T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28007801P 2001-03-30 2001-03-30
US280078P 2001-03-30
PCT/US2002/010097 WO2002079167A1 (en) 2001-03-30 2002-03-28 Geldanamycin derivative and method of treating cancer using same

Publications (2)

Publication Number Publication Date
DE60213386D1 true DE60213386D1 (de) 2006-09-07
DE60213386T2 DE60213386T2 (de) 2006-11-23

Family

ID=23071560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213386T Expired - Lifetime DE60213386T2 (de) 2001-03-30 2002-03-28 Geldanamycinderivate zur krebsbehandlung

Country Status (19)

Country Link
US (1) US6890917B2 (de)
EP (1) EP1373215B1 (de)
JP (1) JP4213472B2 (de)
KR (1) KR100831133B1 (de)
CN (1) CN1262542C (de)
AT (1) ATE334119T1 (de)
AU (1) AU2002307020B2 (de)
CA (1) CA2430692C (de)
CY (1) CY1107484T1 (de)
DE (1) DE60213386T2 (de)
DK (1) DK1373215T3 (de)
ES (1) ES2268068T3 (de)
IL (2) IL156122A0 (de)
MX (1) MXPA03007856A (de)
NZ (1) NZ526133A (de)
PT (1) PT1373215E (de)
SI (1) SI21369A (de)
WO (1) WO2002079167A1 (de)
ZA (1) ZA200304178B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
WO2005009345A2 (en) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
ES2409351T3 (es) 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
MX2007013499A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
EP1906950A4 (de) * 2005-06-21 2008-09-24 Infinity Discovery Inc Ansamycin-formulierungen und anwendungsverfahren dafür
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
WO2007098229A2 (en) * 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
US20070293451A1 (en) * 2006-05-02 2007-12-20 University Of Pittsburgh Regulation ao ApoB by Hsp110 proteins and related compositions and methods
KR100796637B1 (ko) * 2006-09-29 2008-01-22 한국생명공학연구원 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제
CN100500668C (zh) * 2006-12-19 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 格尔德霉素衍生物及其制备方法和制备药物的用途
WO2008094438A1 (en) 2007-01-26 2008-08-07 Kosan Biosciences Incorporated Macrolactams by engineered biosynthesis
US8303960B2 (en) * 2007-02-27 2012-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
EP2190291B1 (de) 2007-08-23 2015-10-14 The Regents of The University of Colorado, A Body Corporate Hsp90-hemmer mit modifizierter toxizität
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
US20090186039A1 (en) * 2008-01-18 2009-07-23 Jang Sung-Key Novel use of grp 94 in virus infection
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US20120283120A1 (en) 2009-09-29 2012-11-08 Takeda Pharmaceutical Company Limited Screening method
CN102030764B (zh) * 2010-11-12 2012-07-04 中国医学科学院医药生物技术研究所 4，5双氢噻嗪酮格尔德霉素及其制备方法
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
CN102603635B (zh) * 2011-01-21 2016-08-03 杭州华东医药集团生物工程研究所有限公司 格尔德霉素衍生物及其制备方法和用途
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2013074695A1 (en) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
CN102552150B (zh) * 2012-03-02 2013-10-30 首都医科大学 一种格尔德霉素脂质体的制备及应用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111470A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Geldanamycin derivative, its preparation, antitumor drug comprising it as active ingredient
JPS55111469A (en) 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
JP2794342B2 (ja) * 1993-06-29 1998-09-03 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
ATE202571T1 (de) * 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO1996034525A1 (en) * 1995-05-02 1996-11-07 The Regents Of The University Of California Inducement of thermotolerance with benzoquinonoid ansamycins
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5948814A (en) * 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
US5952175A (en) * 1997-10-09 1999-09-14 Incyte Pharmaceuticals, Inc. DNA encoding a human progesterone receptor complex p23-like protein
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Also Published As

Publication number Publication date
AU2002307020B2 (en) 2007-06-28
MXPA03007856A (es) 2003-12-04
JP4213472B2 (ja) 2009-01-21
ATE334119T1 (de) 2006-08-15
KR100831133B1 (ko) 2008-05-20
JP2004519514A (ja) 2004-07-02
CA2430692C (en) 2011-05-31
US6890917B2 (en) 2005-05-10
US20040053909A1 (en) 2004-03-18
EP1373215A1 (de) 2004-01-02
CA2430692A1 (en) 2002-10-10
NZ526133A (en) 2005-08-26
CY1107484T1 (el) 2013-03-13
ZA200304178B (en) 2004-02-17
SI21369A (sl) 2004-06-30
PT1373215E (pt) 2006-12-29
CN1484639A (zh) 2004-03-24
IL156122A (en) 2010-11-30
WO2002079167A1 (en) 2002-10-10
IL156122A0 (en) 2003-12-23
DE60213386T2 (de) 2006-11-23
ES2268068T3 (es) 2007-03-16
DK1373215T3 (da) 2006-11-13
EP1373215B1 (de) 2006-07-26
KR20040023581A (ko) 2004-03-18
CN1262542C (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
DE60213386D1 (de) Geldanamycinderivate zur krebsbehandlung
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20014842L (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
IL153426A0 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
TNSN03022A1 (en) Method for treatment of inflammation
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
8364 No opposition during term of opposition